Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tango Therapeutics Inc (TNGX)

Tango Therapeutics Inc (TNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,574,374
  • Shares Outstanding, K 134,677
  • Annual Sales, $ 42,070 K
  • Annual Income, $ -130,300 K
  • EBIT $ -110 M
  • EBITDA $ -112 M
  • 60-Month Beta 1.75
  • Price/Sales 21.63
  • Price/Cash Flow N/A
  • Price/Book 10.42

Options Overview Details

View History
  • Implied Volatility 140.42% (-109.22%)
  • Historical Volatility 98.02%
  • IV Percentile 7%
  • IV Rank 14.46%
  • IV High 777.13% on 05/12/25
  • IV Low 32.80% on 09/04/25
  • Expected Move (DTE 34) 2.59 (19.93%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 399
  • Volume Avg (30-Day) 324
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 5,219
  • Open Int (30-Day) 2,840
  • Expected Range 10.42 to 15.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.31
  • Number of Estimates 6
  • High Estimate -0.28
  • Low Estimate -0.34
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +11.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.30 +56.75%
on 12/24/25
13.18 -1.29%
on 01/16/26
+4.05 (+45.20%)
since 12/16/25
3-Month
6.69 +94.47%
on 10/23/25
13.18 -1.29%
on 01/16/26
+3.84 (+41.88%)
since 10/16/25
52-Week
1.03 +1,163.11%
on 05/08/25
13.18 -1.29%
on 01/16/26
+10.23 (+367.99%)
since 01/16/25

Most Recent Stories

More News
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Founding CEO Barbara Weber, M.D. to become executive chair of the board of directors Malte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately...

TNGX : 13.01 (+11.29%)
Tango Therapeutics Appoints Sung Lee to Board of Directors

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 13.01 (+11.29%)
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled...

TNGX : 13.01 (+11.29%)
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled...

TNGX : 13.01 (+11.29%)
Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled...

TNGX : 13.01 (+11.29%)
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months–  – Combination studies with RAS(ON) inhibitors ongoing, data...

TNGX : 13.01 (+11.29%)
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the...

TNGX : 13.01 (+11.29%)
Tango Therapeutics Announces $225 Million Financing

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 13.01 (+11.29%)
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% –  – Combination studies with RAS(ON) inhibitors ongoing, data...

TNGX : 13.01 (+11.29%)
Biomarker-Driven Therapies And AI Technologies Transform $312B Precision Oncology Market

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline...

CORT : 34.73 (-1.86%)
ARAY : 0.8383 (-3.49%)
KURA : 8.46 (-5.05%)
GTBP : 0.7458 (+2.16%)
TNGX : 13.01 (+11.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 15.53
2nd Resistance Point 14.36
1st Resistance Point 13.68
Last Price 13.01
1st Support Level 11.83
2nd Support Level 10.66
3rd Support Level 9.98

See More

52-Week High 13.18
Last Price 13.01
Fibonacci 61.8% 8.54
Fibonacci 50% 7.11
Fibonacci 38.2% 5.67
52-Week Low 1.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar